Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.44) by 77.27 percent. This is a 70.59 percent increase over losses of $(0.34) per share from the same period last year.
Jim Cramer Pumps The Brakes On Alphabet Sell-Off: ‘It’s Just Got Too Much Going For It’
Cramer initially intended to offload some stock from the CNBC Investing Club's Charitable Trust due to potential threats to Google's search business from new artificial intelligence query systems. However, positive analyst reports on the tech behemoth assuaged his fears.
